The Janssen Pharmaceutical Companies of Johnson & Johnson developed IMBRUVICA® (ibrutinib) the first and only treatment for Chronic Graft-Versus-Host Disease in pediatric patients.
IMBRUVICA® is the only BTKi treatment approved by FDA applicable for individuals with one year and older with chronic graft-versus-host disease (cGVHD) regardless of one or more systemic therapy failures.
IMBRUVICA® is the new oral suspension formulation approved for this life-threatening disease for younger patient’s aging one to less than 12 who had no prior treatment options for cGVHD.
IMBRUVICA® (ibrutinib) is a once-daily oral medication which blocks the Bruton’s tyrosine kinase (BTK) protein required for normal and abnormal B cells to multiply and spread.
IMBRUVICA® blocks the Bruton's tyrosine kinase (BTK) protein, which is needed by normal and abnormal B cells, including specific cancer cells, to multiply and spread. With the BTK blockage, IMBRUVICA® helps abnormal B cells in moving out of their nourishing environments in the lymph nodes, bone marrow, and other organs.
Globally 250,000 patients are treated with IMBRUVICA® and it is approved in more than 100 countries. Most common symptoms of cGVHD include skin rash, mouth sores, dry eyes, liver inflammation, development of scar tissue in the skin and joints, and damaged lungs.
U.S. Food and Drug Administration (FDA) approved IMBRUVICA® (ibrutinib) for the treatment of pediatric patients with chronic graft-versus-host disease (cGVHD).
